Key result
Intravenous glucagon (1-1.5 mg) significantly increased serum IGFBP-1 concentrations at 90 minutes in healthy subjects, GH-deficient patients, and IDDM patients (P<0.05 for all groups).
Why the study?
Does intravenous glucagon stimulate insulin-like growth factor binding protein-1 (IGFBP-1) secretion in healthy subjects and patients with pituitary insufficiency or insulin-dependent diabetes mellitus?
Population
27 individuals including healthy subjects, patients with growth hormone deficiency, and patients with…
Design
Other
Follow-up
180 minutes
Authors
Loading...
Glucagon may directly stimulate IGFBP-1 independent of glucose/insulin; hypothesis-generating in small cohorts and should not yet change practice.
Does intravenous glucagon stimulate insulin-like growth factor binding protein-1 (IGFBP-1) secretion in healthy subjects and patients with pituitary insufficiency or insulin-dependent diabetes mellitus?
p-value: p=<0.05
Glucagon stimulates IGFBP-1 secretion despite increases in glucose and insulin, suggesting it acts as a direct stimulator of IGFBP-1.
Hilding et al. (1993) studied Healthy, Growth Hormone deficiency, Insulin-dependent diabetes mellitus (n=27). Glucagon vs. Baseline was evaluated on Serum IGFBP-1 concentrations at 90 minutes (p=<0.05). Intravenous glucagon (1-1.5 mg) significantly increased serum IGFBP-1 concentrations at 90 minutes in healthy subjects, GH-deficient patients, and IDDM patients (P<0.05 for all groups).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: